Robert P Giugliano MD

Preventive Cardiology, Cardiac Critical Care

Cardiovascular Medicine Brigham and Women's Hospital

TIMI Study Office, Hale BTM Suite 7022, 60 Fenwood RoadBrigham And Womens Hospital Cardiovascualar DivisionBoston, MA 02115
Phone+1 617-278-0317
Fax+1 617-264-5130

Education & Training

Mass General Brigham/Massachusetts General HospitalFellowship, Cardiovascular Disease, 1993 - 1996
Cedars-Sinai Medical CenterResidency, Internal Medicine, 1989 - 1993
Harvard Medical SchoolClass of 1989

PubMed

Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
Andre Zimerman, Ana Laura F Kunzler, Brittany N Weber, Xinhui Ran, Sabina A Murphy
Circulation. 2025-04-21
Long-term visit-to-visit blood pressure variability and risk of cardiovascular and bleeding events: insights from the ENGAGE AF-TIMI 48 trial.
Riccardo Proietti, Michael Gerard Palazzolo, Christian T Ruff, Gregory Y H Lip, Robert P Giugliano
Hypertension Research. 2025-04-01
1 citations
Biomarker-Based Model for Prediction of Ischemic Stroke in Patients With Atrial Fibrillation.
Lars Wallentin, Johan Lindbäck, Ziad Hijazi, Jonas Oldgren, Anthony P Carnicelli
Journal of the American College of Cardiology. 2025-03-25

Journal Articles

Association of Baseline Low-Density Lipoprotein Cholesterol and Percentage Low-Density Lipoprotein Cholesterol Reduction with Statins, Ezetimibe, and PCSK9 Inhibition
Robert P Giugliano, Marc S Sabatine, JAMA Cardiology
Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin Therapy
Prakash Deedwania, Narimon Honarpour, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial Infarction
Christopher E Kurtz, Narimon Honarpour, Marc S Sabatine, Robert P Giugliano, JAMA Cardiology

Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
Efficacy and Safety of PCSK9 Inhibition with Evolocumab in Reducing Cardiovascular Events in Patients with Metabolic Syndrome Receiving Statin TherapyAugust 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
Efficacy of Evolocumab on Cardiovascular Outcomes in Patients with Recent Myocardial InfarctionMay 2020
The Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score, Cardiovascular Risk Stratification and a Strategy for Secondary Prevention with EzetimibeMay 2018
Oral Anticoagulation in Patients with Liver DiseaseMarch 2018
Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
Clinical Events After Interruption of Anticoagulation in Patients with Atrial Fibrillation: An Analysis from the ENGAGE AF-TIMI 48 Trial☆February 2018
Join now to see all

Elderly ASCVD Patients Benefit from Aggressive LDL-Lowering with EvolocumabFebruary 5th, 2025
Association Between Changes in Serial Values of hsTn, Subsequent Cardiovascular EventsJanuary 23rd, 2023
New Analysis Finds Broader Benefit for Post ACS Ezetimibe-Statin ComboOctober 5th, 2021
Join now to see all